Ivermectin Treatment Coverage Validation in Two Onchocerciasis Endemic Districts in Ethiopia: A Community-Based Cross-Sectional Study, 2019

• Published in: Journal of multidisciplinary healthcare Vol. 14; pp. 137 - 144
• Main Authors: Churko, Chuchu, Yihune, Manaye, Teshome, Abinet, Chisha, Yilma, Getachew, Birhanu, Sleshi, Markos, Asfaw, Mekuria Asnakew, Shibiru, Tamiru, Ayele, Nebiyu Negussu, Seife, Fikre, Zerdo, Zerihun, Bekele Kassahun, Alemayehu
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2021; Taylor & Francis Ltd; Dove; Dove Medical Press
• Subjects: Analysis; Blindness; coverage survey; Cross-sectional studies; Data collection; Health aspects; Health risks; Households; Infection; Ivermectin; mass drug administration; Onchocerciasis; Original Research; Parasitic diseases; Public health; Skin diseases; Sociodemographics; Surveys; Tropical diseases; Sub-Saharan Africa; Ethiopia; onchocerciasis; mass drug administration; ivermectin; coverage survey
• ISSN: 1178-2390; 1178-2390
• DOI: 10.2147/JMDH.S288239

Onchocerciasis is the second leading cause of blindness globally next to trachoma, thus eliminating the infection is an important health priority. It is estimated that 15.7 million people are at risk of infection in different parts of Ethiopia. Mass drug administration with ivermectin at community and school level is the basis for control and elimination of onchocerciasis. This study was aimed at validating onchocerciasis treatment coverage in the selected districts of Ethiopia. A community-based cross-sectional study was employed in Itang special and Wombera districts of Ethiopia, from April 1 to 30, 2019 G.C. We used a coverage validation survey builder tool to compute sample size. Individuals aged five years old and above were eligible population. Data were entered into Microsoft Excel and exported to STATA 14 for cleaning and analyses. A chi-square test was used to note statistical association of the outcome variables with independent variables. A total of 3765 individuals were interviewed. Of these, 3244 were offered onchocerciasis treatment. The overall treatment coverage of onchocerciasis in the two selected districts of Ethiopia was 85.9% of the eligible population (3235/3765) (95% CI, 84.8%, 87%). There was significant difference between the two districts in terms of ivermectin offering (X =70.467, <0.001). School attendance was also significantly associated with treatment offering and swallowing status (X =77.29, <0.001; and X =30.581, <0.001). The main reported reasons for not being offered ivermectin were "being absent" (40.86%) and "not knowing about the mass drug administration" (MDA) (25.29%). In conclusion, the treatment coverage of onchocerciasis in this survey was higher than minimum national desired therapeutic coverage. Treatment coverage in Wombera was higher than Itang special district. In addition, children who attended school had a higher chance of swallowing the drug.